Trials / Recruiting
RecruitingNCT06754085
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
A Phase III, Prospective, Open-Label, Single-Arm, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 131 (estimated)
- Sponsor
- HTA Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, 18F-Florastamin PET/CT will be performed in patients with suspected recurrence of prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Florastamin[18F] Injection | The subjects will be intravenously injected with a single dose of 7±1 mCi (259±37 MBq) of Florastamin\[18F\] Injection and undergo PET/CT scan at 60-110 min after the injection. |
Timeline
- Start date
- 2024-12-19
- Primary completion
- 2026-01-01
- Completion
- 2026-05-01
- First posted
- 2024-12-31
- Last updated
- 2024-12-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06754085. Inclusion in this directory is not an endorsement.